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Sustained inhibition of experimental neointimal
hyperplasia with a genetically modified herpes
simplex virus
Michael A. Curi, MD, MPA,a Christopher L. Skelly, MD,a Shari L. Meyerson, MD,a
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Objective: Reported herein is a potential strategy for sustained smooth muscle cell (SMC) inhibition with a virulence-
attenuated herpes simplex virus (HSV). Experiments were conducted in vitro to demonstrate selective SMC cytotoxicity
and in vivo to demonstrate reduced neointimal hyperplasia (NIH) in a clinically relevant animal model.
Methods: In vitro: Cultured human umbilical artery smooth muscle cells (UASMC) and venous endothelial cells
(HUVEC) were exposed to varying multiplicities of infection (MOI) of a 134.5-deleted HSV-1 virus (R849). Cell
survival was assessed at 48 and 72 hours with a colorimetric MTT viability assay. In vivo: New Zealand White rabbit
external jugular veins (n 21) were exposed to R849 (2.5 106 pfu/mL) or culture medium at 110 to 120 mm Hg for
10 minutes, then fashioned as vein patches on carotid arteries. Carotid arteries were ligated distally to decrease blood flow
and stimulate a hyperplastic response (ultra-low shear stress model). After 2, 4, 12, and 24 weeks, patched segments were
perfusion-fixed with glutaraldehyde and morphometrically examined for NIH formation.
Results: In vitro: At 48 hours, R849 exhibited preferential cytotoxicity to UASMC compared with HUVEC, with 11%
10% of UASMCs and 49%  8% of HUVECs surviving after infection with MOI  25 (P < .05). Higher MOI resulted
in poor survival of both cell lines. In vivo: Blood flow was similarly reduced in all animals both at surgery (0.9  0.1
mL/min vs 1.6  0.3 mL/min) and at harvest (2.7  0.4 mL/min vs 2.5  0.5 mL/min). R849-infected patches
exhibited markedly less NIH than control patches did at 2 weeks (162  14 m vs 49  6 m; P < .05), 4 weeks (190
 27 m vs 67  8 m; P < .05), and 12 weeks (233  18 m vs 113  2 m; P < .05).
Conclusion: The virulence-attenuated HSV strain R849 demonstrates selective cytotoxicity for SMC and is capable of
sustained inhibition of NIH in an experimental model of vein graft failure. (J Vasc Surg 2003;37:1294-300.)
Neointimal hyperplasia (NIH) is the pathologic prolif-
eration of vascular smooth muscle cells (SMC) in response
to intervention.1 When severe, the process leads to forma-
tion of new encroaching lesions within the vessel lumen,
reduction in blood flow, and, ultimately, therapeutic fail-
ure. Occurring in 30% of percutaneous coronary angio-
plasty procedures, 50% of peripheral and coronary vein
grafts, and up to 80% of percutaneous procedures per-
formed to treat complex infrainguinal lesions,2,3 this pro-
cess remains the major obstacle to consistent, long-term
success in treatment of arterial occlusive disease. Because
NIH is surprisingly recalcitrant to any form of pharmaco-
logic therapy,4 new methods have been proposed and are
under intense investigation. Much of the focus has been on
genetic therapy, broadly defined as any strategy using re-
combinant nucleic particles, ranging from the very simple
(eg, oligonucleotides) to the complex (eg, adenoviral vec-
tors). The purpose of these experiments was to investigate
the relative cytotoxicity of antiproliferative neurovirulence-
attenuated herpes simplex virus (HSV)–1 (R849) on cul-
tured vascular endothelial cells and SMC and to test the
hypothesis that R849 can prevent formation of ultra-low
shear–induced NIH in a model of a failing vein graft.
METHODS
Vector preparation. The recombinant virus R3617
lacking 1 kb DNA in each copy of the 134.5 gene was
generated by cotransfecting rabbit skin cells with intact
R4002 DNA and DNA of plasmid pRB3616. In this plas-
mid the sequences containing most of the coding domain
of 134.5 have been deleted. The thymidine kinase (TK)–
negative (tk) progeny of the transfection were plated on
143TK-negative cells overlaid with medium containing
bromodeoxyuridine. This procedure selects tk viruses,
and since the tk gene is present in both copies of the 134.5
gene the selected progeny of the transfection can be ex-
pected to contain deletions in both copies. The selected tk
virus was designated as R3617. For assays of neuroviru-
lence, the deletion in the native tk gene of R3617, which
traces its origin from HSV-1 (F)305, had to be repaired.
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This was done by cotransfection of rabbit skin cells with
intact R3617 DNA and BamHI Q fragment containing the
tk gene.5 The virus selected for tk phenotype in 143TK-
negative cells was designated R3616. The bacterial -ga-
lactosidase reporter cassette was then inserted at the 134.5
promotor site of R3616 yielding the R849 strain.6
Cytotoxicity assay. Human umbilical vein endothe-
lial cells (HUVEC; BioWhittaker/Clonetics, Walkersville,
Md) and umbilical artery smooth muscle cells (UASMC;
BioWhittaker/Clonetics) were suspended in complete me-
dium EGM bullet kit and SMGM-2 bullet kit, respectively,
and grown to 100% confluence in P75 flasks in a 37°C
incubator with humidified 5% carbon dioxide (CO2). For
the passage of cells, all reagent pack contents (Hank’s
balanced salt solution [HBSS], trypsin/ethylenediami-
netetraacetic acid [EDTA], Trypsin Neutralizing Solution,
BioWhittaker) were thawed in a 37°C water bath, and the
exhausted media were removed and discarded. Cells were
washed with enough HBSS to cover them, trypsin/EDTA
was added, and flasks were gently agitated under an in-
verted microscope. With loss of adherence of cells, trypsin
was inactivated with an equal volume of TNS. The cells
were centrifuged at 1200 rpm for 5 minutes, and the pellet
was resuspended in complete medium EGM and single-
quots of EGM or in complete medium SMGM-2 with
singlequots of SMGM-2, respectively.
A modified colorimetric assay based on the selective
ability of living cells to reduce the yellow salt MTT (3-[4,5-
dimethylthiozol-2-yl]-2,5 diphenyl tetrazolium bromide;
Sigma-Aldrich, St Louis, Mo) to formazan was used to
quantitate HUVEC and UASMC viability after viral expo-
sure and rescue with Acyclovir (Abbott Laboratories,
North Chicago, Ill). HUVEC and UASMC were sus-
pended in media and plated onto gelatin-coated 96-well
flat-bottom microtiter plates at a density of 5  103 in a
volume of 0.1 mL. Cells were allowed to incubate over-
night and then were exposed to HSV R849 suspended in
HEPES (N-2-hydroxyethylpiperazine-N-2-ethanesulfonic
acid) buffered saline solution (HBS) for 2 hours at 37°C
with humidified 5% CO2 in concentrations of 0, 1, 2.5, 5,
7.5, 10, 25, and 50 MOI. After exposure the viral-contain-
ing fluid was aspirated off, media were replaced, and cells
were returned to the incubator. At 48 and 72 hours the
supernatant was again aspirated, and MTT 5 mg/mL was
added to each well of the zero plate for 4 hours at 37°C.
After formation of the formazan crystals, the supernatant
was aspirated with attention to not disturb the underlying
cell layer. The formazan crystals were then dissolved in 0.1
mL dimethyl sulfoxide (DMSO; Sigma), absorbance was
measured at 515 nm with a microplate spectrophotometer
(SpectraMax 340 004, Molecular Devices Corporation,
Sunnyvale, Calif) interfaced with a personal computer (Ap-
ple Macintosh, Cupertino, Calif), and relative cell survival
was calculated. The experiment was repeated twice again.
To assess acyclovir rescue, HUVEC and UASMC were
suspended in media and plated as described. Cells were
allowed to incubate overnight and then were exposed to
HSV R849 suspended in HBS for 2 hours at 37°C with
humidified 5% CO2 at a concentration of 25 MOI. The
supernatant was aspirated, 0.1 mL of complete medium
EGM or complete medium SMGM-2 containing 0, 0.25,
0.5, 1.0, 2.5, 5.0, or 10 g/mL of acyclovir was added to
each well, and the cells were returned to the incubator. At
72 hours the supernatant was again aspirated and MTT 5
mg/mL was added to each well of the zero plate and
incubated for 4 hours at 37°C. The supernatant was then
aspirated with attention to not disturb the underlying cell
layer. The formazan crystals were dissolved in 0.1 mL
DMSO, and absorbance was measured as described. The
experiment was repeated twice again.
Animal operations. Animals were cared for in accor-
dance with the University of Chicago Institutional Animal
Care and Use Committee. Male New Zealand White rab-
bits (3.5-4 kg) were anesthetized with intramuscular injec-
tion of ketamine hydrochloride (40 mg/kg) and xylazine
(5 mg/kg) augmented with isoflurane (0%-3%) titrated for
effect via endotracheal intubation. Antibiotic prophylaxis
was provided with enrofloxacin 10 mg/kg intramuscularly
daily for 2 days. Intra-arterial pressure was monitored
through a 22-gauge cannula placed in the contralateral ear
artery. Using sterile technique, the external jugular vein
was exposed and doubly cannulated with 22-gauge olive-
tipped cannulas. One cannula was used for irrigation and
infection, and the other was used for intraluminal pressure
monitoring. The main channel was infected with either
vehicle (n 10) or R849 2.5 106 pfu/mL (n 8) for 10
minutes at 110 mm Hg.
After infection, the vein was irrigated with saline solu-
tion, excised, and bivalved. The ipsilateral common carotid
artery (CCA) was then exposed through the same incision,
and the animal was systemically anticoagulated with hepa-
rin 200 U/kg intravenously. The CCA was doubly
clamped, and a 1.5 cm longitudinal arteriotomy performed
proximal to the cranial thyroid artery branch. The arteriot-
omy was reconstructed with external jugular vein patch
angioplasty with running 8-0 polypropylene suture (TE-
145; Davis-Geck, Manatee, PR) under 4.3 loupe magni-
fication. To reduce flow, the CCA was ligated distal to the
small cranial thyroid artery branch. Ultrasonic transit-time
flow through the graft was measured (HT207; Transonics
Systems, Ithaca, NY) and recorded with a digital data
acquisition system (Lab Master DMA; Scientific Solutions,
Solon, Ohio). External measurements were made with
digital calipers. The incision was closed, and the animals
were allowed to recover. Anticoagulation was not reversed.
Harvest and analysis. After 2, 4, 12, or 24 weeks
postoperative, the animals were anesthetized again and the
vein patches reexposed. Intra-arterial pressure and blood
flow through the patch were again measured and recorded.
The proximal CCA was cannulated with an olive-tipped
cannula on a three-way stopcock attached to a syringe and
manometer. The artery was ligated distal to the patch, and
the section was perfusion-fixed with 1.25% glutaraldehyde
at 100 mm Hg for 10 minutes, excised, and divided into
three sections, starting 1 mm distal to the beginning of the
patch and ending 1 mm proximal to its end point. A 0.5
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mm section was prepared with standard gold coating, and
the endothelium was visualized with scanning electron
microscopy. Five-millimeter sections were cut from each of
the portions of the patch and stained with eosin, hematox-
ylin-eosin, and Weigert–van Gieson stain.
Three sections of each specimen were used for histo-
morphometric analysis. Digital images were acquired with a
microscope equipped with a 3.0 mega pixel digital camera
(Olympus, Melville, NY). Thickness of the neointima was
digitally measured (Adobe Photoshop 6.0, San Jose, Calif)
at 10 points along the venous patch from lumen to internal
elastic lamina. Mean thickness was calculated by taking the
average of all measurements. Statistical analysis was per-
formed using SPSS 8.0 software (SPSS, Chicago, Ill).
Comparison of differences in variance in the MTT assay
was assessed with analysis of variance. Comparison of
thickness was achieved with the Mann-Whitney U test
for nonparametric variables. Significance was assigned at
P 	 .05.
RESULTS
In vitro results. HUVEC infected with R849 at MOI
of 1 had a relative cell survival of 86%
 8% at 48 hours and
81% 
 4% at 72 hours. UASMC infected with R849 at
MOI of 1 had a relative cell survival of 92% 
 10% at 48
hours and 73%
 6% at 72 hours. As expected, a decreasing
proportion of cells survived with increasing viral concentra-
tions, with only 49% 
 8% of HUVEC and 11% 
 10% of
UASMC surviving 48 hours after infection with MOI of 25
(P 	 .001 when compared with MOI  0). No cells
survived to 72 hours at this viral concentration. UASMC
showed significantly worse survival after infection with
R849 than HUVEC did at 48 hours over a wide range of
MOI (Fig 1).
HUVEC infected with 25 MOI of R849 and rescued
with 0.25 g/mL and 0.5 g/mL of acyclovir had a
relative cell survival at 72 hours of 45%
 5% (P	 .01) and
85% 
 9% (P 	 .01), respectively, compared with 0%
survival without acyclovir. UASMC infected with 25 MOI
of R849 could not be rescued even with 10 g/mL of
acyclovir (Fig 2).
In vivo results. All animal operations were completed
without complication, and 21 of 22 vein patches remained
patent at harvest. There was no significant difference in
mean blood flow in vehicle-treated versus viral-treated
patches at implantation or harvest (Table). However, the
amount of NIH was significantly reduced in the R849-
treated groups after 2, 4, and 12 weeks (P 	 .05; Fig 1).
The reduction in NIH translated into an enhanced flow
lumen, as evidenced by increased lumen radius in R849-
treated patches after 4 weeks. Decreased NIH and en-
hanced flow lumen in R849-treated patches seemed to be
sustained after 24 weeks as well (Fig 3), although the small
number of animals (n  2 in each group) precluded statis-
tical comparison.
Fig 1. Relative cell survival of umbilical artery smooth muscle cells (open circles) and human umbilical vein endothelial
cells (closed circles) at various multiplicities of infection of R849 demonstrating preferential cytotoxicity for smooth
muscle cells.
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DISCUSSION
HSV-1 is a lytic, nonintegrating DNA virus that has
demonstrated neurotropism and establishment of long-
term infections.7 Like adenovirus, HSV-1 can be manufac-
tured in high titer, and it contains multiple nonessential
genes that can potentially be deleted to reduce virulence or
house transgenes. This had led some investigators to pre-
dict that HSV may become a major genetic agent for
treatment of systemic disease.8-10 However, the lytic and
highly infectious nature of HSV and the lifelong potential
for latency necessitate significant genetic engineering be-
fore therapeutic use.
HSV-1 has been extensively studied as therapy for
malignant tumors of the central nervous system with a
variety of genetic manipulations.7,11-14 Its use in vascular
tissue is limited, although there are a few reports of success-
ful use of vascular SMCs,15 skeletal muscle cells,16-18 and
cardiac myocytes.19 It was first proposed to use viruses that
lack TK, ribonucleotide reductase, or glycoprotein H cod-
ing regions, which reduced viral growth in nondividing
cells.15,20-22 A second strategy, and the one proposed
herein, centers on deletion of both copies of the 134.5
gene.5,23 The products of the 134.5 gene allow replication
in the central nervous system, and phosphorylation of the 
subunit of the translation initiation factor eiF-2 involved in
viral protein synthesis. Deletion of both copies of this gene
potentially decreases virulence but still allows replication in
dividing cells and possibly in stable episomal infection.
Furthermore, the 134.5-deleted strain retains TK activity
and thus is potentially controllable with exogenous acyclo-
vir.
The herpes family of viruses may be the ideal agents for
antiproliferative vascular gene therapy. They are highly
penetrant in vascular tissue,15 capable of generating pro-
longed infection in immunocompetent hosts,10,24 strong
inhibitors of the mammalian cell cycle,23,25 and potentially
Effect of R849 on experimental vein patches
2 Weeks 4 Weeks 12 Weeks
Control R849 Control R849 Control R849
Mean blood flow at surgery (mL/min) 1.0 
 0.4 1.5 
 0.3 0.8 
 0.5 1.8 
 0.7 0.8 
 0.1 1.0 
 0.3
Mean blood flow at harvest (mL/min) 1.6 
 0.8 1.0 
 0.6 1.7 
 1.3 3.2 
 1.9 3.7 
 0.9 5.2 
 3.4
Neointimal hyperplasia (m) 162 
 15 49 
 6* 190 
 27 67 
 9* 233 
 18 113 
 2*
*P 	 .05 compared with control.
Fig 2. Relative cell survival of umbilical artery smooth muscle cells (open circles) and human umbilical vein endothelial
cells (closed circles) after infection with R849 at MOI of 25 and then rescued with varying concentration of acyclovir.
Note almost complete rescue of endothelial cells but not smooth muscle cells.
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controllable with well-tolerated exogenous antiviral
agents.26 In a particularly noteworthy study by Miyatake et
al15 a conditionally replication-competent HSV strain
(hrR3) effectively inhibited SMC proliferation in culture
and in a rat model of arterial restenosis. In human beings,
replication-competent HSV has been used as experimental
treatment of malignant glioma.7,14,27 The agent is well-
tolerated, and preliminary data are encouraging.
The hypothesis under study in this experiment was that
a highly attenuated HSV mutant, R849, would be effica-
cious in preventing experimental pathologic vascular pro-
liferation. Exposure of cultured vascular cells to R849 at
MOI of 10 resulted in significant cytotoxicity, which was
even more pronounced at higher viral concentrations and
was completely reversible with acyclovir. R849 seems to
have a predilection for SMCs over endothelial cells, a useful
Fig 3. Effect of R849 on outflow-restricted vein patches after 2 weeks (A, B), 4 weeks (C, D), 12 weeks (E, F) and
24 weeks (G, H). Control patches (A, C, E, G) exhibited pronounced neointimal hyperplasia at all time points, which
was significantly reduced with treatment with R849 (B, D, F, H) (Weigert–van Giesen stain, 40 magnification).
Vascular reconstruction is composed of vein patch (top half) and native artery (bottom half).
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biologic property, given the need to preserve the anti-
thrombotic endothelial cell layer while maximizing SMC
inhibition. Indeed, R849 failed to induce thrombosis in
this animal model even while mean blood flow was reduced
to less than 6 mL/min for as long as 24 weeks.
R849 treatment significantly inhibited formation of
NIH in this study. NIH was reduced by 50% to 70%,
depending on the time point tested, and the effect was
sustained over 6 months. In control animals, the chroni-
cally reduced shear stress appeared to slowly cause thicken-
ing and contraction of the vein patch reconstruction. In
contrast, prevention of the thickening response with pre-
treatment with R849 rendered the patches thinner and
larger, altering the chronic response to low shear. This was
achieved with viral concentrations of only 106 pfu/mL,
about 104 less than concentrations used in traditional ad-
enoviral strategies.28-33 The actual amount and duration of
infection was not specifically quantified in this study, al-
though a previous report documented significant infection
persisting up to 4 weeks,6 and others have reported persis-
tence for as long as 1 year.10
In summary, the virulence-attenuated HSV strain
R849 demonstrates differential cytotoxicity for SMC and is
capable of sustained inhibition of NIH in an experimental
model of vein graft failure. Attenuated HSV may be a viable
agent for prevention or treatment of vascular proliferative
disorders.
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